ZM 447439Aurora Kinase inhibitor,potent and selective CAS# 331771-20-1 |
- MLN8237 (Alisertib)
Catalog No.:BCC2166
CAS No.:1028486-01-2
- VX-680 (MK-0457,Tozasertib)
Catalog No.:BCC2167
CAS No.:639089-54-6
- CYC116
Catalog No.:BCC2181
CAS No.:693228-63-6
- AZD1152
Catalog No.:BCC1393
CAS No.:722543-31-9
- MK-8745
Catalog No.:BCC3994
CAS No.:885325-71-3
- GSK1070916
Catalog No.:BCC2183
CAS No.:942918-07-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 331771-20-1 | SDF | Download SDF |
PubChem ID | 9914412 | Appearance | Powder |
Formula | C29H31N5O4 | M.Wt | 513.59 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (194.71 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-[4-[[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino]phenyl]benzamide | ||
SMILES | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5 | ||
Standard InChIKey | OGNYUTNQZVRGMN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C29H31N5O4/c1-36-26-18-24-25(19-27(26)38-15-5-12-34-13-16-37-17-14-34)30-20-31-28(24)32-22-8-10-23(11-9-22)33-29(35)21-6-3-2-4-7-21/h2-4,6-11,18-20H,5,12-17H2,1H3,(H,33,35)(H,30,31,32) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Novel, selective ATP-competitive inhibitor of Aurora B kinase in vitro (IC50 values are 50, 250 and 1000 nM for Aurora B, C and A kinases respectively). Selective over a range of other kinases including cdk1 and PLK1 (IC50 > 10 μM). Inhibits cell division and displays selective toxicity towards proliferating tumor cells versus non-dividing cells. |
ZM 447439 Dilution Calculator
ZM 447439 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9471 mL | 9.7354 mL | 19.4708 mL | 38.9416 mL | 48.677 mL |
5 mM | 0.3894 mL | 1.9471 mL | 3.8942 mL | 7.7883 mL | 9.7354 mL |
10 mM | 0.1947 mL | 0.9735 mL | 1.9471 mL | 3.8942 mL | 4.8677 mL |
50 mM | 0.0389 mL | 0.1947 mL | 0.3894 mL | 0.7788 mL | 0.9735 mL |
100 mM | 0.0195 mL | 0.0974 mL | 0.1947 mL | 0.3894 mL | 0.4868 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ZM 447439 is a novel, potent and selective inhibitor of Aurora kinase, a family of serine/threonine kinases essential for accurate chromosome segregation during cell division, that inhibits the activity of purified recombinant Aurora A and Aurora B proteins in vitro with 50% inhibition concentration IC50 values of 110 nM and 130 nM respectively and hence inhibits phosphorylation of histone H3 on serine 10. Being specifically for Aurora kinases, ZM 447439 barely inhibits the majority of other protein kinases (IC50 > 10 μM), such as CDK1/2/4, IKK1/2, PLK1, CHK1, cFLT2, KDR2, FAK and Zap-70, except for MEK1, SRC and LCK (IC50 values of 1.79 μM, 1.03 and 0.88 μM respectively μM).
Reference
Li M, Jung A, Ganswindt U, Marini P, Friedl A, Daniel PT, Lauber K, Jendrossek V, Belka C. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochem Pharmacol. 2010 Jan 15;79(2):122-9. doi: 10.1016/j.bcp.2009.08.011. Epub 2009 Aug 15.
Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol. 2003 Apr 28;161(2):267-80.
Long ZJ, Xu J, Yan M, Zhang JG, Guan Z, Xu DZ, Wang XR, Yao J, Zheng FM, Chu GL, Cao JX, Zeng YX, Liu Q. ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture. Cell Cycle. 2008 May 15;7(10):1473-9. Epub 2008 Mar 12.
- 10-Demethoxy-10-(diethylamino)colchicine
Catalog No.:BCC8164
CAS No.:6962-03-4
- Bisdemethoxycurcumin
Catalog No.:BCN5975
CAS No.:33171-05-0
- DMPO
Catalog No.:BCC7684
CAS No.:3317-61-1
- AZ 10417808
Catalog No.:BCC2356
CAS No.:331645-84-2
- CFM 4
Catalog No.:BCC8017
CAS No.:331458-02-7
- trans-2,3,4-Trimethoxycinnamic acid
Catalog No.:BCN5035
CAS No.:33130-03-9
- Etomidate
Catalog No.:BCC1150
CAS No.:33125-97-2
- Boc-D-Phg-OH
Catalog No.:BCC3315
CAS No.:33125-05-2
- LG 101506
Catalog No.:BCC7696
CAS No.:331248-11-4
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- Stephavanine
Catalog No.:BCN5253
CAS No.:33116-33-5
- PT 1
Catalog No.:BCC7846
CAS No.:331002-70-1
- 2-(N,N-Dimethylamino)acetophenone
Catalog No.:BCN1747
CAS No.:3319-03-7
- 2',4'-Dihydroxy-7-methoxy-8-prenylflavan
Catalog No.:BCN6844
CAS No.:331954-16-6
- I2906
Catalog No.:BCC1637
CAS No.:331963-29-2
- Nτ-Methyl-His-OH
Catalog No.:BCC2957
CAS No.:332-80-9
- Telatinib (BAY 57-9352)
Catalog No.:BCC3879
CAS No.:332012-40-5
- H-Ala-NH2.HCl
Catalog No.:BCC2688
CAS No.:33208-99-0
- TCS 5861528
Catalog No.:BCC7816
CAS No.:332117-28-9
- Glucosyringic acid
Catalog No.:BCN5254
CAS No.:33228-65-8
- DZ2002
Catalog No.:BCC5544
CAS No.:33231-14-0
- Rutaevin
Catalog No.:BCN6993
CAS No.:33237-37-5
- 1,7-Bis(4-hydroxyphenyl)hepta-4,6-dien-3-one
Catalog No.:BCN7092
CAS No.:332371-82-1
- Strychnistenolide
Catalog No.:BCN8039
CAS No.:332372-09-5
ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture.[Pubmed:18418083]
Cell Cycle. 2008 May 15;7(10):1473-9.
Mitotic Aurora kinases are essential for accurate chromosome segregation during cell division. Forced overexpression of Aurora kinase results in centrosome amplification and multipolar spindles, causing aneuploidy, a hallmark of cancer. ZM447439 (ZM), an Aurora selective ATP-competitive inhibitor, interferes with the spindle integrity checkpoint and chromosome segregation. Here, we showed that inhibition of Aurora kinase by ZM reduced histone H3 phosphorylation at Ser10 in Hep2 carcinoma cells. Multipolar spindles were induced in these ZM-treated G(2)/M-arrested cells with accumulation of 4N/8N DNA, similar to cells with genetically suppressed Aurora-B. Cells subsequently underwent apoptosis, as assessed by cleavage of critical apoptotic associated protein PARP. Hep2 cells formed a tumor-like cell mass in 3-dimensional matrix culture; inhibition of Aurora kinase by ZM either destructed the preformed cell mass or prevented its formation, by inducing apoptotic cell death as stained for cleaved caspase-3. Lastly, ZM inhibition of Aurora kinase was potently in association with decrease of Akt phosphorylation at Ser473 and its substrates GSK3alpha/beta phosphorylation at Ser21 and Ser9. Together, we demonstrated that Aurora kinase served as a potential molecular target of ZM for more selective therapeutic cancer treatment.
Validating Aurora B as an anti-cancer drug target.[Pubmed:16912073]
J Cell Sci. 2006 Sep 1;119(Pt 17):3664-75.
The Aurora kinases, a family of mitotic regulators, have received much attention as potential targets for novel anti-cancer therapeutics. Several Aurora kinase inhibitors have been described including ZM447439, which prevents chromosome alignment, spindle checkpoint function and cytokinesis. Subsequently, ZM447439-treated cells exit mitosis without dividing and lose viability. Because ZM447439 inhibits both Aurora A and B, we set out to determine which phenotypes are due to inhibition of which kinase. Using molecular genetic approaches, we show that inhibition of Aurora B kinase activity phenocopies ZM447439. Furthermore, a novel ZM compound, which is 100 times more selective for Aurora B over Aurora A in vitro, induces identical phenotypes. Importantly, inhibition of Aurora B kinase activity induces a penetrant anti-proliferative phenotype, indicating that Aurora B is an attractive anti-cancer drug target. Using molecular genetic and chemical-genetic approaches, we also probe the role of Aurora A kinase activity. We show that simultaneous repression of Aurora A plus induction of a catalytic mutant induces a monopolar phenotype. Consistently, another novel ZM-related inhibitor, which is 20 times as potent against Aurora A compared with ZM447439, induces a monopolar phenotype. Expression of a drug-resistant Aurora A mutant reverts this phenotype, demonstrating that Aurora A kinase activity is required for spindle bipolarity in human cells. Because small molecule-mediated inhibition of Aurora A and Aurora B yields distinct phenotypes, our observations indicate that the Auroras may present two avenues for anti-cancer drug discovery.
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.[Pubmed:16451062]
J Med Chem. 2006 Feb 9;49(3):955-70.
The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory activity and excellent selectivity against a panel of various serine-threonine and tyrosine kinases, as exemplified by compound 46. We found also that the position and nature of the substituent on the thiazole play key roles in cellular potency. Compounds with an acetanilide substituent at C5' have the greatest cellular activity. The importance of the C5' position for substitution has been rationalized by ab initio molecular orbital calculations. Results show that the planar conformation with the sulfur of the thiazole next to the quinazoline N-3 is strongly favored over the other possible planar conformation. Compound 46 is a potent suppressor of the expression of phospho-histone H3 in tumor cells in vitro as well as in vivo, where 46, administered as its phosphate prodrug 54, suppresses the expression of phospho-histone H3 in subcutaneously implanted tumors in nude mice.
Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.[Pubmed:12719470]
J Cell Biol. 2003 Apr 28;161(2):267-80.
The Aurora/Ipl1 family of protein kinases plays multiple roles in mitosis and cytokinesis. Here, we describe ZM447439, a novel selective Aurora kinase inhibitor. Cells treated with ZM447439 progress through interphase, enter mitosis normally, and assemble bipolar spindles. However, chromosome alignment, segregation, and cytokinesis all fail. Despite the presence of maloriented chromosomes, ZM447439-treated cells exit mitosis with normal kinetics, indicating that the spindle checkpoint is compromised. Indeed, ZM447439 prevents mitotic arrest after exposure to paclitaxel. RNA interference experiments suggest that these phenotypes are due to inhibition of Aurora B, not Aurora A or some other kinase. In the absence of Aurora B function, kinetochore localization of the spindle checkpoint components BubR1, Mad2, and Cenp-E is diminished. Furthermore, inhibition of Aurora B kinase activity prevents the rebinding of BubR1 to metaphase kinetochores after a reduction in centromeric tension. Aurora B kinase activity is also required for phosphorylation of BubR1 on entry into mitosis. Finally, we show that BubR1 is not only required for spindle checkpoint function, but is also required for chromosome alignment. Together, these results suggest that by targeting checkpoint proteins to kinetochores, Aurora B couples chromosome alignment with anaphase onset.